Standard BioTools Inc. is a life science tools company providing instrumentation, consumables, and services for proteomics and genomics research. The company's core platforms include CyTOF for mass cytometry, Hyperion for spatial biology and imaging mass cytometry, and Biomark for high-throughput genomics and qPCR applications. It serves academic research institutions, biopharmaceutical companies, and clinical research laboratories in North America, Europe, and Asia-Pacific. Standard BioTools manufactures microfluidics instruments and reagents in Singapore and Canada, and offers lab services including panel design, sample preparation, and custom conjugation. The company recently sold its SomaLogic and Sengenics subsidiaries, which operated the SomaScan aptamer-based proteomics business, to Illumina.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Instruments & Supplies Homepage standardbio.com
Sector Healthcare IR page investors.standardbio.com
Tags
mass cytometry, spatial biology, genomics, proteomics, microfluidics, qpcr, life science tools, research use only, CyTOF, Hyperion, Biomark, Biomark X9, LyoMax, Maxpar, Imaging Mass Cytometry, SomaLogic, Sengenics, SomaScan, KREX, Single SOMAmer, D3 Assay Design
Press page investors.standardbio.com/press-releases

Metrics

Valuation  
Market cap $ 246.788M
Market cap (USD) $ 246.788M
P/E -4.17
PEG —
P/BV 0.44
P/S 2.92
P/OCF -3.84
P/FCF -3.76
Dividend yield —
Turnover / mcap —
Returns  
ROE -16.7%
ROI -17.6%
ROIC -19.5%
Profit margin -87.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 0.07%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 8
Quality score -70.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 85.331M 174.432M 106.34M 97.948M 130.581M 138.144M 117.243M 112.964M 101.937M 104.446M 114.712M 116.456M 71.183M 52.334M 42.865M 33.56M 25.412M
Net profit -74.896M -138.885M -74.656M -190.098M -59.237M -53.02M -64.79M -59.013M -60.535M -75.985M -53.315M -52.83M -16.526M -19.024M -22.47M -16.902M -19.128M
Free cash flow -82.646M -151.809M -46.118M -93.195M -57.325M -28.134M -37.741M -25.573M -25.664M -44.163M -38.678M -30.026M -5.037M -19.862M -19.218M -13.047M -20.312M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 1.28 1.75 2.21 1.17 3.92 6 3.48 8.62 5.89 7.28 10.81 33.73 38.3 14.31 — 4.6 —
Price performance 12m -0.27 -0.21 0.89 -0.7 -0.35 0.72 -0.6 0.46 -0.19 -0.33 -0.68 -0.12 1.68 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 14.6M 15M 16.7M 19M 25.4M 18.3M 17.3M 19.7M 33.6M 13.4M
↳ YoY growth -42.6% +3.0% +10.6% +14.0% +33.9% -27.9% -5.7% +13.8% +70.9% -60.0%
↳ 5y CAGR +9.6% +3.1% +9.6% -3.2% 0.0% +4.6% +2.8% +3.4% +12.1% -12.0%
Lease liabilities (USD) — — 0.00 6.16M 41.2M 40.6M 37.8M 34.7M 32.7M 30.5M
Cash and deposits (USD) 35M 58.1M 95.4M 21.7M 68.5M 28.5M 81.3M 51.7M 167M 121M
Intangible assets (USD) 79.8M 68.6M 57.4M 46.2M 40.2M 27.9M 12.6M 1.4M 29M —
Right-of-use assets (USD) — — 0.00 4.86M 38.1M 37.1M 33.9M 30.7M 28.8M 26.7M
Cash flow detail
Operating cash flow (USD) -39.1M -24.1M -25.2M -35.2M -15.4M -44.1M -89.4M -43.3M -143M -74.3M
Purchases of property, plant and equipment (USD) -5.07M -1.57M -372,000 -2.53M -12.7M -13.3M -3.83M -2.83M -8.36M -8.3M
Purchases of intangible assets (USD) 0.00 -50,000 0.00 0.00 — — — — — —
Change in receivables (cash effect) (USD) 10.5M -554,000 -1.79M -2.08M -7.63M 6.73M 1.06M -2.99M 8.97M -1.36M
Change in inventories (cash effect) (USD) -3.39M 4.6M 1.49M -2.69M -8.64M -4.78M -8.47M -4.91M -9.88M -11.5M
Change in payables (cash effect) (USD) -2.27M 585,000 -294,000 2.15M 3.36M 1.28M -2.78M 1.62M -13M 2.44M
Share buybacks (cash effect) (USD) — — — — — 0.00 -563,000 -5.41M -40.5M 0.00
Interest paid (cash effect) (USD) -5.53M -5.53M -5.53M -3.54M -3.09M -3.15M -3.49M -3.82M -3.09M -15,000
Income taxes paid (cash effect) (USD) -355,000 -245,000 -321,000 -205,000 -521,000 -2.09M -309,000 -801,000 -607,000 73,000
Share-based compensation (USD) 13.9M 9.09M 11M 11.4M 14.5M 16.1M 14.9M 13.1M 31.7M 29.6M
Operating cash flow before change in receivables (USD) -49.6M -23.5M -23.4M -33.1M -7.79M -50.8M -90.4M -40.3M -152M -73M
Free cash flow (OCF - PPE - intangibles) (USD) -44.2M -25.7M -25.6M -37.7M -28.1M -57.3M -93.2M -46.1M -152M -82.6M
Income detail
Research and development expense (USD) 38.4M 30.8M 30M 31.6M 36.5M 37.9M 38.5M 25.9M 62.4M 26M
↳ 5y CAGR +22.5% +13.2% +8.5% -6.1% -1.5% -0.2% +4.5% -2.9% +14.6% -6.5%
Total comprehensive income (USD) -75.6M -60.3M -59.1M -64.7M -52.3M -60.3M -191M -75M -135M -77.6M
Comprehensive income to owners (USD) -75.6M -60.3M -59.1M -64.7M -52.3M -60.3M -191M -75M -135M -77.6M
Reported Mar 3, 2017 Mar 8, 2018 May 7, 2019 Feb 27, 2020 Feb 25, 2021 Mar 14, 2023 Mar 14, 2023 Mar 1, 2024 Mar 11, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Standard BioTools Inc. — Other Events Bull 0 Bear 0 Routine

As previously disclosed, on June 6, 2026, Standard BioTools Inc., a Delaware corporation (“Standard BioTools” or the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) by and among the Company, Treeline Biosciences, Inc., a Delaware corporation (“Treeline”), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”). Pursuant to the Merger Agreement, on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Treeline (the “Merger”), with Treeline surviving the Merger as a wholly owned subsidiary of the Company.

In connection with the Merger and related stockholder vote, the Company filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (File No. 333-297560), as amended (the “Registration Statement”), which was declared effective by the SEC on October 21, 2026. The Registration Statement includes a proxy statement/prospectus with respect to the special meeting of the Company’s stockholders scheduled to be held on November 19, 2026 (the “Special Meeting”) in connection with the Merger.

On November 3, 2026, Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), issued a joint press release with ARCHIMED, a leading investment firm focused exclusively on healthcare industries (“ARCHIMED”), announcing the closing of Standard BioTools’ previously announced sale of its Microfluidics business to ARCHIMED. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Forward-Looking Statements

The words “strengthen,” “support,” “expand,” “invest,” “enable,” “accelerate,” “advance,” “improve,” “aim,” “create,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Nov 3, 2026

PDF Version

Business will operate as Biomark Scientific, a leader in accessible, scalable and automated genomic workflows powered by proprietary microfluidics technology

BOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Global private equity healthcare specialist ARCHIMED, and Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools”), today announced the completion of ARCHIMED’s previously announced acquisition of Standard BioTools’ Microfluidics Business. As part of ARCHIMED, the business enters its next chapter as a standalone business under the name Biomark Scientific.

Biomark Scientific, an innovative microfluidics technology tools provider specializing in high-throughput and multi-assay genomics systems, will offer versatile and scalable genomic profiling on its flagship Biomark™ platform. The next-generation Biomark X9 system is the only automated PCR, qPCR and NGS library prep system on the market, performing simultaneous profiling of multiple types of genomic assay readouts in a single run using patented integrated fluidic circuits (IFCs).

A highly regarded brand in high-throughput genomic workflows serving research institutions, public health laboratories and biobanks, Biomark was previously part of Fluidigm, which was founded in 1999 and renamed Standard BioTools in 2022. As Biomark Scientific, the business will continue to offer its automated bench-top system that can run genomics assays with robustness, speed and precision, driving quality insights for critical, time-sensitive data.

Within ARCHIMED, Biomark Scientific plans to build on its established technology, expertise and deep customer relationships, while expanding its capabilities and supporting scientific discovery across genomics, clinical research and public health. The company will be an independent entity comprised of the same dedicated team and supported by enhanced capabilities to provide seamless continuity of the products and services that customers and partners trust.

“This is an exciting step forward for our organization, strengthening our ability to serve and support our customers and partners,” says Luke Stewart, newly appointed Chief Commercial Officer of Biomark Scientific. “Together with ARCHIMED, expanding our resources and investing in our expertise reflects our continued commitment to delivering greater value to our customers, with the reliability and quality they depend on. This partnership enables us to confidently move into this next phase while staying true to our foundation of scientific excellence and exceptional service, all in support of advancing genomics and improving public health.”

“With Biomark Scientific’s accelerating position in the clinical research and public health markets, we are poised to support the company in fortifying global growth and launching the business as a primary player in the industry,” says Michael Goetter at ARCHIMED. “Biomark Scientific is comprised of an amazing team, well-positioned to maintain their current momentum with the rigor and meticulous drive that has instilled loyalty among the genomics community.”

About ARCHIMED

With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €15 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

About Standard BioTools Inc.

Standard BioTools Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Standard BioTools’ established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/notices. Trademarks: standardbio.com/legal/terms-and-conditions/.

Patent and License Information: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. All rights reserved.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the disposition of Standard BioTools’ Microfluidics Business. The words “strengthen,” “support,” “expand,” “invest,” “enable,” “accelerate,” “advance,” “improve,” “aim,” “create,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) the future conduct and growth of the Microfluidics Business and the markets in which ARCHIMED operates; (ii) the success of products and services competitive with the Microfluidics Business; (iii) ARCHIMED’s ability to successfully integrate the Microfluidics Business into its existing operations and the Microfluidics Business’s technology and products into its portfolio; (iv) ARCHIMED’s ability to sell the products and further develop the Microfluidics Business’s technology; (v) ARCHIMED’s ability to successfully manage partner and customer relationships in the market; and (vi) customer uptake of, and satisfaction with, new products and services.

For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2026, Standard BioTools’ most recent Quarterly Report on Form 10-Q and Standard BioTools’ other filings with the SEC. Should any of these risks or uncertainties materialize, actual results could differ materially from expectations. These forward-looking statements speak only as of the date hereof. Standard BioTools does not assume any obligation to, and does not currently intend to, update any such forward-looking statements except as may be required by law.

Additional Information and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed transactions involving Standard BioTools and Treeline Biosciences, Inc. (“Treeline”) and/or Standard BioTools’ sale of its Mass Cytometry business to Element Biosystems, LLC (“Element”). In connection with the Treeline transaction and related stockholder vote, Standard BioTools has filed with the SEC a registration statement on Form S-4, as amended (the “Form S-4”), which was declared effective by the SEC on October 21, 2026. The Form S-4 includes a definitive proxy statement and a definitive prospectus of Standard BioTools. The definitive proxy statement/prospectus, dated October 21,2026, was first mailed to stockholders of Standard BioTools on or about October 21, 2026. This communication is not a substitute for the definitive proxy statement/prospectus or any other document that Standard BioTools may file with the SEC or send to its stockholders in connection with the proposed transactions. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

INVESTORS AND STOCKHOLDERS OF STANDARD BIOTOOLS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS, SUPPLEMENTS AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND OTHER RELEVANT MATERIALS FILED OR TO BE FILED WITH THE SEC BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED TRANSACTIONS BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT STANDARD BIOTOOLS, TREELINE, ELEMENT AND THE PROPOSED TRANSACTIONS. Copies of the materials filed or to be filed by Standard BioTools with the SEC may be obtained free of charge on Standard BioTools’ Investor Relations website at https://investors.standardbio.com or by contacting Standard BioTools’ Investor Relations department at [email protected]. In addition, all of those materials are available at no charge on the SEC’s website at www.sec.gov.

Participants in the Solicitation

Standard BioTools, Treeline and certain of their respective directors, executive officers, other members of management and employees may be deemed to be participants in the solicitation of proxies of Standard BioTools stockholders in connection with the proposed transactions under SEC rules. Investors and stockholders may obtain more detailed information regarding the names, affiliations and interests of Standard BioTools’ executive officers and directors who may, under SEC rules, be deemed participants in the solicitation by reading Standard BioTools’ proxy statement for its 2026 annual meeting of stockholders (including under the headings “Management and Corporate Governance,” “Executive Officer and Director Compensation,” “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,” “Executive Compensation” and “Certain Relationships and Related Transactions, and Director Independence”), its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and Standard BioTools’ other filings with the SEC. Information regarding Treeline’s directors and executive officers who may be deemed participants in the solicitation is contained in the proxy statement/prospectus filed by Standard BioTools. These documents are available free of charge at the SEC’s website at www.sec.gov or by going to Standard BioTools’ Investor Relations website at http://investors.standardbio.com or contacting Standard BioTools’ Investor Relations department at [email protected].

Prompts

Standard BioTools Inc. (ticker LAB), listed in United States.

Company History

Date Change Detail
Apr 1, 2022 Renamed FLUIDIGM CORP → STANDARD BIOTOOLS INC.

ETFs Holding Standard BioTools Inc.

ETF Weight in ETF Shares Market value As of
MSSM 0.01% 123,265 $ 81.195K Aug 31, 2026